FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2022-04-01 | 6-K | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES | View Document |
| 2022-03-28 | 6-K | PUBLICATION OF 2022 AGM NOTICE | View Document |
| 2022-03-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-24 | 6-K | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL | View Document |
| 2022-03-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-23 | 6-K | ISSUANCE OF NOTES | View Document |
| 2022-03-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| 2022-03-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-08 | 6-K | GSK ANNUAL REPORT 2021 ON FORM 20-F | View Document |
| 2022-03-08 | IRANNOTICE | IRANNOTICE | View Document |
| 2022-03-08 | 20-F | 20-F | View Document |
| 2022-03-04 | 6-K | GSK PUBLISHES ANNUAL REPORT 2021 | View Document |
| 2022-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA | View Document |
| 2022-02-28 | 6-K | FOMR 6-K | View Document |
| 2022-02-28 | 6-K | FORM 6-K | View Document |
| 2022-02-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-24 | 6-K | CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE | View Document |
| 2022-02-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-22 | 6-K | GSK CONSUMER HEALTHCARE TO BE CALLED HALEON | View Document |
| 2022-02-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-18 | 6-K | GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-14 | SC 13G | SC 13G | View Document |
| 2022-02-14 | 6-K | TRANSFER OF TREASURY SHARES | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document |
| 2022-02-10 | SC 13G | SCHEDULE 13G | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document |
| 2022-02-10 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2022-02-10 | 6-K | BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS | View Document |
| 2022-02-09 | 6-K | FINAL RESULTS | View Document |
| 2022-02-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-07 | SC 13G/A | View Document | |
| 2022-02-07 | 6-K | PUBLICATION OF FULL YEAR 2021 RESULTS | View Document |
| 2022-02-02 | 6-K | GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD | View Document |
| 2022-02-01 | 6-K | FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA | View Document |
| 2022-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-01-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | TONY WOOD APPOINTED CSO DESIGNATE, GSK | View Document |
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-18 | 6-K | UPDATE - GSK CONSUMER HEALTHCARE | View Document |
| 2022-01-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-11 | 6-K | US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES | View Document |
| 2022-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-21 | 6-K | VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE | View Document |
| 2021-12-20 | 6-K | CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED | View Document |
| 2021-12-17 | 6-K | XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 | View Document |
| 2021-12-15 | 6-K | GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE | View Document |
| 2021-12-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-07 | 6-K | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA | View Document |
| 2021-12-07 | 6-K | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document |
| 2021-12-02 | 6-K | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document |
| 2021-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-11-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-24 | 6-K | GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES | View Document |
| 2021-11-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-17 | 6-K | NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS | View Document |
| 2021-11-15 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2021-11-12 | 6-K | PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB | View Document |
| 2021-11-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-05 | 6-K | GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT | View Document |
| 2021-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-10-27 | 6-K | 3RD QUARTER RESULTS | View Document |
| 2021-10-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-27 | 6-K | DIRECTORATE CHANGE | View Document |
| 2021-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
